製薬における人工知能(AI)の世界市場

Artificial Intelligence (AI) in Pharmaceuticals: Global Markets

製薬における人工知能(AI)の世界市場

商品番号 : SMB-87716

出版社BCC Research
出版年月2025年9月
ページ数139
価格タイプシングルユーザライセンス
価格USD 4,650
種別英文調査報告書

製薬における人工知能(AI)の世界市場は、2025 年から 2030 年にかけて年平均成長率 (CAGR) 31.7% で成長し、2025 年の 38 億ドルから 2030 年末までに 152 億ドルに達すると予測されています。

製薬業界において、AIはもはや未来的な概念ではなく、戦略的に不可欠な要素となっています。創薬の初期段階から、標的の特定と分子設計を劇的に加速させることで、AIはあらゆるものを変革します。また、患者募集の強化と転帰予測による臨床試験の最適化にも貢献しています。研究開発の枠を超え、AIは予知保全と品質管理(QC)を通じて製造プロセスを合理化し、正確な需要予測とリアルタイムの在庫最適化によってサプライチェーン管理に革命をもたらし、最終的には市場投入までの時間の短縮、コスト削減、そして患者一人ひとりに合わせたよりパーソナライズされた治療の提供につながります。データ統合、規制の枠組み、専門知識の獲得といった課題は依然として残っていますが、実証可能なメリットと拡大するユースケースは、製薬業界におけるイノベーションと競争優位性のための基盤技術としてAIが注目されるという市場の質的なトレンドを裏付けています。

製薬における人工知能(AI)の世界市場に関する本レポートは、市場のダイナミクスとトレンドを探り、技術開発、ソフトウェアの性能、臨床試験、新製品承認、そして新興技術を分析しています。また、主要企業の概要と戦略も掲載しています。

本レポートでは、AIが診断能力の向上、疾患の早期発見、臨床試験の最適化、創薬、個別化治療計画を通じて、医薬品業界にどのような変革をもたらしているかを考察しています。さらに、業界横断的かつバリューチェーンの各段階におけるAIのディスラプション(創造的破壊)を検証し、市場支出パターン、投資予測、研究開発費、ベンチャーキャピタルによる資金調達状況も示しています。本レポートでは、市場を製品タイプ、アプリケーション、地域別にセグメント化しています。タイプにはソフトウェアとサービスが含まれます。アプリケーションには、創薬・開発、臨床試験、個別化医療などが含まれます。対象地域は、北米、欧州、アジア太平洋、その他世界の4地域です。市場予測については、2024年を基準年とし、2025年から2030年までの予測を提供しています

Report Highlights

The global market for artificial intelligence (AI) in pharmaceuticals is estimated to grow from $3.8 billion in 2025 to reach $15.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 31.7% from 2025 through 2030.

Summary:

In the pharmaceutical industry, AI is no longer a futuristic concept but a strategic imperative, transforming everything from early-stage drug discovery, where it drastically accelerates target identification and molecule design, to optimizing clinical trials by enhancing patient recruitment and predicting outcomes. Beyond R&D, AI is streamlining manufacturing processes through predictive maintenance and quality control (QC), and revolutionizing supply chain management with accurate demand forecasting and real-time inventory optimization, ultimately leading to faster time-to-market, reduced costs, and the promise of more personalized therapies for patients. While challenges remain in data integration, regulatory frameworks and expertise acquisition, the demonstrable benefits and expanding use cases underscore a qualitative market trend toward AI as a foundational technology for innovation and competitive advantage in pharma.

Report Scope

This report on the global market for AI in pharmaceuticals explores market dynamics and trends, and analyzes technological developments, software performance, clinical trials, new product approvals and emerging technologies. The report also includes profiles of leading companies and their strategies.

The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.

Report Synopsis

Report MetricsDetails
Base year considered2024
Forecast period considered2025-2030
Base year market size$3.0 Billion
Market size forecast$15.2 Billion
Growth rateCAGR of 31.7% from 2025 to 2030
Units considered$ Millions
Segments coveredProduct Type, Application and Region
Regions coveredNorth America, Europe, Asia-Pacific, and the Rest of the World (RoW)
Key Market Drivers
  • Increasing adoption of AI in clinical trials.
  • Faster drug discovery and development.
  • Demand for precision medicine and AI applications.
Companies studied
AICUREATOMWISE INC.
BENEVOLENTAIGOOGLE DEEPMIND
HEALXIKTOS
INSILICO MEDICINEINVENIAI LLC.
NVIDIA CORP.PATHAI INC.
RECURSIONSCHRODINGER INC.
SYRENCLOUD INC.TEMPUS AI INC.
XTALPI INC.

Report Includes

– 27 data tables and 62 additional tables

– An analysis of the global markets for artificial intelligence (AI) in the pharmaceuticals industry

– Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030

– Estimates of the market’s size and revenue growth prospects, accompanied by a market share analysis by product type, application and region

– Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables

– Insights derived from Porter’s Five Forces model, as well as a global supply chain analysis

– Case studies on AI implementation to streamline processes across drug discovery and development, manufacturing, quality control and patient care

– A relevant patent analysis, featuring key granted and published patents

– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies

– Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook

– Profiles of the leading companies, including Google DeepMind, Atomwise Inc., Insilico Medicine, Recursion Pharmaceuticals and Nvidia Corp.

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Market Dynamics and Growth Factors

Emerging Technologies

Segmental Analysis

Regional Analysis

Conclusion

Chapter 2 Market Overview

Current Market Overview

Macroeconomic Factors Analysis

Government Policy and Regulation

Technological Infrastructure and Digital Readiness

Global Trade and Supply Chain Dynamics

Impact of U.S. Tariffs

Porter’s Five Forces Analysis

Potential for New Entrants (Moderate to High)

Bargaining Power of Suppliers (Low to Moderate)

Bargaining Power of Buyers (High)

Threat of Substitute Products or Services (Low to Moderate)

Industry Level of Competitiveness (High)

AI’s Impact on the Pharmaceutical Value Chain

Drug Discovery and Preclinical Development: Accelerated Innovation

Clinical Trials: Smarter Design and Execution

Manufacturing and Supply Chain: Intelligent Operations

Regulatory Affairs and Compliance: Automation and Accuracy

Commercialization and Market Access: Data-Driven Strategies

Post-Market Surveillance: Continuous Learning and Safety Monitoring

Use Cases

Use Case 1: Generative AI for Efficiency in Regulatory Submissions

Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes

Chapter 3 Market Dynamics

Market Dynamics

Market Drivers

Faster Drug Discovery and Development

Increasing Adoption of AI in Clinical Trials

Demand for Precision Medicine and AI Applications

Market Restraints

Regulatory and Ethical Concerns

Data Challenges

Market Opportunities

Collaborations and Investments

Increased Focus on Drug Discovery in Emerging Nations

Advances of Generative AI in Molecular Design

Chapter 4 Regulatory Landscape

Overview

Regulatory Scenario in the U.S.

Regulatory Scenario in Europe

Regulatory Scenario in Japan

Regulatory Scenario in China

Other Countries

Chapter 5 Emerging Trends and Pipeline Analysis

Emerging Trends

Generative AI in Pharma

Federated Learning

Natural Language Processing

Generative Adversarial Networks

Pipeline Analysis

Takeaways

Patent Analysis

Findings

Chapter 6 Market Segment Analysis

Segmentation Breakdown

Market Breakdown, by Product Type

Takeaways

Software

Services

Market Breakdown, by Application

Takeaways

Drug Discovery and Development

Clinical Trials

Personalized Medicine

Other Applications

Geographic Breakdown

Market Breakdown, by Region

Takeaways

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Chapter 7 Competitive Intelligence

Takeaways

Competitive Analysis

Strategic Analysis

Investment Landscape

Chapter 8 Sustainability in AI in the Pharmaceutical Industry: ESG Perspective

Introduction to ESG

Sustainability Trends and Initiatives

ESG Risk Ratings

Concluding Remarks from BCC Research

Chapter 9 Appendix

Research Methodology

Sources

Abbreviations

Company Profiles

AICURE

ATOMWISE INC.

BENEVOLENTAI

GOOGLE DEEPMIND

HEALX

IKTOS

INSILICO MEDICINE

INVENIAI LLC.

NVIDIA CORP.

PATHAI INC.

RECURSION

SCHRODINGER INC.

SYRENCLOUD INC.

TEMPUS AI INC.

XTALPI INC.

Emerging Start-ups/Market Disruptors。

List of Tables

Summary Table : Global Market for AI in Pharmaceuticals, by Region, Through 2030

Table 1 : Collaborations Between AI Software and Pharmaceutical Companies

Table 2 : FDA AI/ML Initiatives and Milestones, 2014 and 2025

Table 3 : EMA AI/ML Regulatory Development Timeline, 2021–2024

Table 4 : Clinical Trial Data for AI in Pharmaceutical Drugs, 2025

Table 5 : Granted Patents for AI in Pharmaceuticals, 2022–2025

Table 6 : Global Market for AI in Pharmaceuticals, by Product Type, Through 2030

Table 7 : Global Market for AI Software in Pharmaceuticals, by Region, Through 2030

Table 8 : Global Market for Services in AI in Pharmaceuticals, by Region, Through 2030

Table 9 : Global Market for AI in Pharmaceuticals, by Application, Through 2030

Table 10 : AI Tools Used in Drug Discovery

Table 11 : AI-Enabled Drugs Entering the Clinical Phase, 2025

Table 12 : Global Market for AI in Drug Discovery and Development, by Region, Through 2030

Table 13 : Partnerships Between Pharmaceutical and Technology Companies, 2023–2025

Table 14 : Advantages and Disadvantages of Using AI in Clinical Trials

Table 15 : Global Market for AI in Pharmaceuticals for Clinical Trial Applications, by Region, Through 2030

Table 16 : Applications of ML in Pharmacogenomics

Table 17 : Global Market for AI in Pharmaceuticals for Personalized Medicine, by Region, Through 2030

Table 18 : Global Market for Other Applications of AI in Pharmaceuticals, by Region, Through 2030

Table 19 : Global Market for AI in Pharmaceuticals, by Region, Through 2030

Table 20 : North American Market for AI in Pharmaceuticals, by Product Type, Through 2030

Table 21 : North American Market for AI in Pharmaceuticals, by Application, Through 2030

Table 22 : North American Market for AI in Pharmaceuticals, by Country, Through 2030

Table 23 : European Market for AI in Pharmaceuticals, by Product Type, Through 2030

Table 24 : European Market for AI in Pharmaceuticals, by Application, Through 2030

Table 25 : European Market for AI in Pharmaceuticals, by Country, Through 2030

Table 26 : Asia-Pacific Market for AI in Pharmaceuticals, by Product Type, Through 2030

Table 27 : Asia-Pacific Market for AI in Pharmaceuticals, by Application, Through 2030

Table 28 : Asia-Pacific Market for AI in Pharmaceuticals, by Country, Through 2030

Table 29 : RoW Market for AI in Pharmaceuticals, by Product Type, Through 2030

Table 30 : RoW Market for AI in Pharmaceuticals, by Application, Through 2030

Table 31 : RoW Market for AI in Pharmaceuticals, by Sub-Region, Through 2030

Table 32 : Leading Companies in the Global Market for AI in Pharmaceuticals, 2024

Table 33 : Agreements, Collaborations and Partnerships in the Market for AI in Pharmaceuticals, 2022–2025

Table 34 : M&A in the AI in Pharmaceuticals Industry, 2024–2025

Table 35 : Recent Investments in the AI in Pharmaceuticals Industry, 2024 and 2025

Table 36 : ESG Risk Rankings for AI in Pharmaceuticals Companies, 2025*

Table 37 : Information Sources Used in this Report

Table 38 : Abbreviations Used in this Report

Table 39 : AiCure: Company Snapshot

Table 40 : AiCure: Product Portfolio

Table 41 : AiCure: News/Key Developments, 2024

Table 42 : Atomwise Inc.: Company Snapshot

Table 43 : Atomwise Inc.: Product Portfolio

Table 44 : Atomwise Inc.: News/Key Developments, 2022

Table 45 : BenevolentAI: Company Snapshot

Table 46 : BenevolentAI: Product Portfolio

Table 47 : BenevolentAI: News/Key Developments, 2022–2025

Table 48 : Google DeepMind: Company Snapshot

Table 49 : Google DeepMind: Product Portfolio

Table 50 : Google DeepMind: News/Key Developments, 2024 and 2025

Table 51 : Healx: Company Snapshot

Table 52 : Healx: Product Portfolio

Table 53 : Healx: News/Key Developments, 2023 and 2024

Table 54 : Iktos: Company Snapshot

Table 55 : Iktos: Product Portfolio

Table 56 : Iktos: News/Key Developments, 2023–2025

Table 57 : Insilico Medicine: Company Snapshot

Table 58 : Insilico Medicine: Product Portfolio

Table 59 : Insilico Medicine: News/Key Developments, 2023–2025

Table 60 : InveniAI LLC.: Company Snapshot

Table 61 : InveniAI LLC.: Product Portfolio

Table 62 : InveniAI LLC.: News/Key Developments, 2021–2024

Table 63 : Nvidia Corp.: Company Snapshot

Table 64 : Nvidia Corp.: Financial Performance, FY 2023 and 2024

Table 65 : Nvidia Corp.: Product Portfolio

Table 66 : Nvidia Corp.: News/Key Developments, 2023–2025

Table 67 : PathAI Inc.: Company Snapshot

Table 68 : PathAI Inc.: Product Portfolio

Table 69 : PathAI Inc.: News/Key Developments, 2024 and 2025

Table 70 : Recursion: Company Snapshot

Table 71 : Recursion: Financial Performance, FY 2023 and 2024

Table 72 : Recursion: Product Portfolio

Table 73 : Recursion: News/Key Developments, 2024 and 2025

Table 74 : Schrödinger Inc.: Company Snapshot

Table 75 : Schrödinger Inc.: Financial Performance, FY 2023 and 2024

Table 76 : Schrödinger Inc.: Product Portfolio

Table 77 : Schrödinger Inc.: News/Key Developments, 2023 and 2024

Table 78 : SyrenCloud Inc.: Company Snapshot

Table 79 : SyrenCloud Inc.: Product Portfolio

Table 80 : Tempus AI Inc.: Company Snapshot

Table 81 : Tempus AI Inc.: Financial Performance, FY 2023 and 2024

Table 82 : Tempus AI Inc.: Product Portfolio

Table 83 : Tempus AI Inc.: News/Key Developments, 2023–2025

Table 84 : XtalPi Inc.: Company Snapshot

Table 85 : XtalPi Inc.: Financial Performance, FY 2023 and 2024

Table 86 : XtalPi Inc.: Product Portfolio

Table 87 : XtalPi Inc.: News/ Key Developments, 2024 and 2025

Table 88 : Emerging Startups in the Market for AI in Pharmaceuticals

List of Figures

Summary Figure : Global Market Shares of AI in Pharmaceuticals, by Region, 2024

Figure 1 : Applications of AI in the Drug Development and Distribution Life Cycle

Figure 2 : Porter’s Five Forces Analysis: AI in Pharmaceuticals Market

Figure 3 : Applications of AI in the Pharmaceutical Value Chain

Figure 4 : Market Dynamics of AI in Pharmaceuticals

Figure 5 : Emerging Technologies of AI in the Pharmaceutical Market

Figure 6 : Granted Patents for AI in Pharmaceuticals, by Year, 2021–2025

Figure 7 : Global Market Shares of AI in Pharmaceuticals, by Product Type, 2024

Figure 8 : Global Market Shares of AI Software in Pharmaceuticals, by Region, 2024

Figure 9 : Global Market Shares of Services for AI in Pharmaceuticals, by Region, 2024

Figure 10 : Global Market Shares of AI in Pharmaceuticals, by Application, 2024

Figure 11 : Role of AI in Drug Discovery

Figure 12 : Global Market Shares of AI in Drug Discovery and Development, by Region, 2024

Figure 13 : Global Market Shares of AI in Pharmaceuticals for Clinical Trial Applications, by Region, 2024

Figure 14 : Global Market Shares of AI in AI in Pharmaceuticals for Personalized Medicine, by Region, 2024

Figure 15 : Global Market Shares of Other Applications of AI in Pharmaceuticals, by Region, 2024

Figure 16 : Global Market Shares of AI in Pharmaceuticals, by Region, 2024

Figure 17 : North American Market Shares of AI in Pharmaceuticals, by Product Type, 2024

Figure 18 : North American Market Shares of AI in Pharmaceuticals, by Application, 2024

Figure 19 : North American Market Shares of AI in Pharmaceuticals, by Country, 2024

Figure 20 : European Market Shares of AI in Pharmaceuticals, by Product Type, 2024

Figure 21 : European Market Shares of AI in Pharmaceuticals, by Application, 2024

Figure 22 : European Market Shares of AI in Pharmaceuticals, by Country, 2024

Figure 23 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Product Type, 2024

Figure 24 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Application, 2024

Figure 25 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Country, 2024

Figure 26 : RoW Market Shares of AI in Pharmaceuticals, by Product Type, 2024

Figure 27 : RoW Market Shares of AI in Pharmaceuticals, by Application, 2024

Figure 28 : RoW Market Shares of AI in Pharmaceuticals, by Sub-Region, 2024

Figure 29 : Biopharma AI Investment, 2019–2024

Figure 30 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024

Figure 31 : Nvidia Corp.: Revenue Share by Country/Region, FY 2024

Figure 32 : Schrödinger Inc.: Revenue Share, by Business Unit, FY 2024

Figure 33 : Schrödinger Inc.: Revenue Share, by Country/Region, FY 2024

Figure 34 : Tempus AI Inc.: Revenue Share, by Business Unit, FY 2024

Figure 35 : XtalPi Inc.: Revenue Share, by Business Unit, FY 2024

Figure 36 : XtalPi Inc.: Revenue Share, by Country/Region, FY 2024